ClinicalTrials.gg
RecruitingNCT03954431LowerDoseBCTUpdated Aug 24, 2025

High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)

An interventional study of Dedicated breast CT(BCT) in Breast Cancer, sponsored by University of Arizona. Recruiting at 1 site in United States. Open to female participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by University of Arizona · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Not applicable
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Breast Neoplasms by University of Arizona — 3 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · University of Arizona.

Planned enrollment
Largest of 28
600 · median 28
Started
2025
with 1 other
No phase
10 of 32
2 open now
Registered
24th of 32
by date

Among the 32 studies in Breast Neoplasms by University of Arizona, this one has the largest planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 24th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 32 studies in Breast Neoplasms by University of Arizona are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Neoplasms by University of Arizona, or all of them as a file.
02

Study summary

This study is being performed to find out if a new kind of breast imaging (called dedicated breast CT or BCT) can help doctors to see the small structures in breast tissue more clearly. The investigators also want to find out if using the BCT will provide a more accurate diagnosis of breast cancer.

Read the detailed description

The breast imaging device that will be used in this study (breast computed tomography or BCT) is not FDA-approved for this use so this is a research study. The machine has been redesigned to see if doctors can see smaller structures and use a lower radiation dose.

The breast CT device will take multiple pictures of the subject's breast and create a 3-D image of the breast. It does not compress or squash the breast like a mammogram.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria: All subjects that are eligible to participate in the study will be women who satisfy all of the inclusion criteria stated below:

  • who are 40 years of age or older (typical screening age range)
  • who are undergoing or scheduled for screening or diagnostic imaging, or need a to investigate an abnormality in the breast.

Exclusion criteria: Subjects that present with any of the criteria listed below will be excluded:

  • Males,
  • women less than 40 years old,
  • women unable to self-consent,
  • prisoners,
  • pregnant, suspected to be pregnant, or lactating women (self-reported)
  • women with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker;
  • women who are unable to tolerate study constraints, frail, or unable to cooperate;
  • women who weigh more than 440 lbs (200 Kg), which is the weight limit for the patient support table of the BCT system;
  • women who have received radiation treatments to the thorax for malignant and nonmalignant conditions, such as (but not limited to) treatment for enlarged thymus gland as an infant, irradiation for benign breast conditions, including breast inflammation after giving birth, and treatment for Hodgkin's disease;
  • women who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram;
  • women who have received large number of diagnostic x-ray examinations for monitoring of disease such as (but not limited to) tuberculosis, and severe scoliosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Dedicated breast computed tomography (BCT)

    All subjects will undergo bilateral breast CT (BCT) imaging exam.

    Diagnostic Test: Dedicated breast CT(BCT)

Interventions

  • Diagnostic testDedicated breast CT(BCT)

    The breast CT device will take multiple pictures of the subject's uncompressed breast and creates a 3-D image of the breast.

    Also known as: BCT

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy

    The diagnostic accuracy of BCT will be determined from a multi-reader, multi-case reader study.

    Time frame: 12 months after completion of accrual

07

Study locations

1 of 1 sites recruiting
  • University of Arizona
    Tucson, Arizona 85724, United States
    Recruiting
    • Michele Galvan, R.T. · Contactmngalvan@arizona.edu · 520-626-2279
    • Srinivasan Vedantham, PhD · Principal investigator
    • Alan J-T Chiang, MD, PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 40 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 17, 2019
StartActual
Aug 14, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03954431
Responsible party
Sponsor
First posted
May 17, 2019
Start date
Aug 14, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Aug 24, 2025

Study contacts

Michele Galvan, R.T.R.
Contact
mngalvan@arizona.edu
520-626-2279
Srinivasan Vedantham, PhD
principal investigator · University of Arizona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion